Stay updated on Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial
Sign up to get notified when there's something new on the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page.

Latest updates to the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page
- Check2 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1, indicating a version update. The Back to Top element was removed, a minor navigation change.SummaryDifference0.1%
- Check9 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%
- Check16 days agoChange DetectedThe web page has been updated to include new facility names and specific locations in Spain, while removing several previous location references and related topics. Additionally, the page now features updated information on uveal melanoma and tislelizumab.SummaryDifference4%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check45 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.7%
Stay in the know with updates to Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page.